Glenmark had in May intimated the study to examine whether early administration of a combination of Favipiravir and Umifenovir enhances ant...

However, the experts were not convinced and decided not to put it in the revised treatment protocol,” a person aware of the matter told ET ...

The Mumbai-based company had received approval from Drug Controller General of India (DCGI) last month to conduct clinical trials of Favipi...

The drug sold under brand name Avigan by Fujifilm Toyama Chemical has demonstrated activity against influenza viruses and has been approved...

Data available in the public domain shows Malpani Hospital has conducted over 40 clinical trials for osteoarthritis and rheumatoid arthriti...

The apex drug regulatory body has sent show cause notices to Glenmark as well as the investigator in charge of the trial at the hospital, s...

The issue has escalated to a point where even the Central Drugs Standard Control Organisation, India's apex drug regulatory body, has sent ...

Glenmark has completed the pre-clinical evaluation for its bi-specific antibody GBR 1302 and filed the phase I trial application for the sa...

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 is entering human trials.

GBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).

Glenmark Pharmaceuticals said it has entered the phase II clinical trials for its new drug molecule aimed at treating ulcerative colitis.

Glenmark Pharmaceuticals on Wednesday said it has started Phase-IIb human trials of its 'Revamilast' molecule.

Glenmark Pharmaceuticals has complained to the drug regulator that the government-funded research centre, Guru Govind Singh Hospital in Jam...

Glenmark Pharmaceuticals on Friday said it would look at out-licensing two of its molecules this year that are in clinical trials.

Drug firm Glenmark pharmaceuticals on Friday said it will file an application with American health regulator US Food and Drug Administrator...

Market participants expect payout to Glenmark from such a deal would include upfront and milestone payments and royalties on sales.

Glenmark Pharmaceuticals’ much-hyped asthma research molecule Oglemilast (code name GRRC 3886), is witnessing slower clinical progress, put...